

---

## ... BIBLIOGRAPHY ...

- Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. *Clin Ther* 1993; 15:917-926.
- Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases. *Clin Drug Invest* 1996;11:289-299.
- Andreasen NC. Assessment issues and the cost of schizophrenia. *Schizophr Bull* 1991;17:475-481.
- Caton CLM, Koh SP, Fleiss JL, et al. Rehospitalization in chronic schizophrenia. *J Nerv Ment Dis* 1985;173:139-148.
- Cavallero R, Smeraldi E. Antipsychotic-induced tardive dyskinesia: Recognition, prevention and management. *CNS Drugs (New Zealand)* 1995;4:278-293.
- Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. *Am J Psychiatry* 1995;152:1724-1729.
- Keck PE, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. *J Clin Psychiatry* 1995;56:466-470.
- Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. *Clin Ther* 1995;17:402-412.
- Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 1994;151:825-835.
- Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. *Am J Psychiatry* 1993;150:1630-1638.
- National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses. *Am J Psychiatry* 1993;150:1447-1465.
- Negrón AE, Leiderman EA, Parkadavil M, et al. A naturalistic outcome study of risperidone treatment among state hospital patients. *Psychiatric Services* 1996;47: 1118-1120.
- Reid WH, Mason M, Toprac M. Savings in hospital bed days related to treatment with clozapine. *Hosp Community Psychiatry* 1994;45:261-264.
- Revicki DA, Luce BR, Wechsler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. *Hosp Community Psychiatry* 1990;41:850-854.
- Rice DP, Kelman S, Miller LS. The economic burden of mental illness. *Hosp Community Psychiatry* 1992;43: 1227-1232.
- Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology*. Washington, DC: American Psychiatric Press; 1995:636.
- Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursements benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. *N Engl J Med* 1994;331:650-655.